PF-Atlas › Clinical Trials › NCT07349394
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor on the PK of Rosuvastatin in Healthy Participants
VNZ/TEZ/D-IVA · Phase 1
Registry ID
NCT07349394
Phase
Phase 1
Status
Completed
Drug / intervention
VNZ/TEZ/D-IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2026-01-12
Enrollment
18
Locations
1
About this trial
The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07349394 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.